Table 2.
Correlation between ELF3-AS1 expression and clinical characteristics of HCC.
| Characteristic | Low expression of ELF3-AS1 | High expression of ELF3-AS1 | P |
|---|---|---|---|
| n | 187 | 187 | |
| T stage, n (%) | 0.002 | ||
| T1 | 107 (28.8%) | 76 (20.5%) | |
| T2 | 36 (9.7%) | 59 (15.9%) | |
| T3 | 38 (10.2%) | 42 (11.3%) | |
| T4 | 3 (0.8%) | 10 (2.7%) | |
|
| |||
| N stage, n (%) | 0.623 | ||
| N0 | 124 (48.1%) | 130 (50.4%) | |
| N1 | 1 (0.4%) | 3 (1.2%) | |
|
| |||
| M stage, n (%) | 0.124 | ||
| M0 | 129 (47.4%) | 139 (51.1%) | |
| M1 | 0 (0%) | 4 (1.5%) | |
|
| |||
| Pathologic stage, n (%) | 0.003 | ||
| Stage I | 102 (29.1%) | 71 (20.3%) | |
| Stage II | 33 (9.4%) | 54 (15.4%) | |
| Stage III | 38 (10.9%) | 47 (13.4%) | |
| Stage IV | 1 (0.3%) | 4 (1.1%) | |
|
| |||
| Tumor status, n (%) | 0.101 | ||
| Tumor free | 110 (31%) | 92 (25.9%) | |
| With tumor | 69 (19.4%) | 84 (23.7%) | |
|
| |||
| Gender, n (%) | 0.008 | ||
| Female | 48 (12.8%) | 73 (19.5%) | |
| Male | 139 (37.2%) | 114 (30.5%) | |
|
| |||
| Race, n (%) | 0.037 | ||
| Asian | 70 (19.3%) | 90 (24.9%) | |
| Black or African American | 12 (3.3%) | 5 (1.4%) | |
| White | 100 (27.6%) | 85 (23.5%) | |
|
| |||
| Age, n (%) | 0.277 | ||
| ≤60 | 83 (22.3%) | 94 (25.2%) | |
| >60 | 104 (27.9%) | 92 (24.7%) | |
|
| |||
| Weight, n (%) | 0.272 | ||
| ≤70 | 88 (25.4%) | 96 (27.7%) | |
| >70 | 88 (25.4%) | 74 (21.4%) | |
|
| |||
| Height, n (%) | 0.130 | ||
| <170 | 94 (27.6%) | 107 (31.4%) | |
| ≥170 | 78 (22.9%) | 62 (18.2%) | |
| BMI, n (%) | 0.296 | ||
| ≤25 | 84 (24.9%) | 93 (27.6%) | |
| >25 | 86 (25.5%) | 74 (22%) | |
|
| |||
| Residual tumor, n (%) | 0.004 | ||
| R0 | 172 (49.9%) | 155 (44.9%) | |
| R1 | 3 (0.9%) | 14 (4.1%) | |
| R2 | 0 (0%) | 1 (0.3%) | |
|
| |||
| Histologic grade, n (%) | < 0.001 | ||
| G1 | 41 (11.1%) | 14 (3.8%) | |
| G2 | 94 (25.5%) | 84 (22.8%) | |
| G3 | 47 (12.7%) | 77 (20.9%) | |
| G4 | 2 (0.5%) | 10 (2.7%) | |
|
| |||
| Adjacent hepatic tissue inflammation, n (%) | 0.025 | ||
| None | 73 (30.8%) | 45 (19%) | |
| Mild | 44 (18.6%) | 57 (24.1%) | |
| Severe | 10 (4.2%) | 8 (3.4%) | |
|
| |||
| Albumin(g/dl), n (%) | 0.982 | ||
| <3.5 | 36 (12%) | 33 (11%) | |
| ≥3.5 | 118 (39.3%) | 113 (37.7%) | |
|
| |||
| AFP (ng/ml), n (%) | < 0.001 | ||
| ≤400 | 119 (42.5%) | 96 (34.3%) | |
| >400 | 18 (6.4%) | 47 (16.8%) | |
|
| |||
| Prothrombin time, n (%) | 0.889 | ||
| ≤4 | 104 (35%) | 104 (35%) | |
| >4 | 46 (15.5%) | 43 (14.5%) | |
|
| |||
| Child-Pugh grade, n (%) | 0.176 | ||
| A | 110 (45.6%) | 109 (45.2%) | |
| B | 14 (5.8%) | 7 (2.9%) | |
| C | 1 (0.4%) | 0 (0%) | |
|
| |||
| Fibrosis Ishak score, n (%) | 0.526 | ||
| 0 | 43 (20%) | 32 (14.9%) | |
| 1/2 | 13 (6%) | 18 (8.4%) | |
| 3/4 | 15 (7%) | 13 (6%) | |
| 5/6 | 45 (20.9%) | 36 (16.7%) | |
|
| |||
| Vascular invasion, n (%) | 0.037 | ||
| No | 114 (35.8%) | 94 (29.6%) | |
| Yes | 46 (14.5%) | 64 (20.1%) | |
|
| |||
| Age, median (IQR) | 63 (53, 69) | 60 (51, 68) | 0.239 |